Response to Comments: Erythropoiesis Stimulating Agents

This document (A59114) is a response-to-comments notice for the ESA Local Coverage Determination L39237 and does not itself state clinical coverage criteria. For specific indications, limitations, documentation requirements, and frequency limits for erythropoiesis stimulating agents, refer to LCD L39237 (notice began 2022-06-09, effective 2022-07-24).

"This document is a response-to-comments notice regarding Local Coverage Determination (LCD) L39237 for Erythropoiesis Stimulating Agents (ESAs); it does not itself establish clinical coverage crite..."

Sign up to see full coverage criteria, indications, and limitations.